(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3...s physically demanding - or who do shift work - co... A major study in the US showed that this heavy wo...ood pressure and underweight babies. Jobs which i...shift work and fatiguing work were also significan...
...the triptans are known to help counter the unpleas...re seven different triptan drugs available, it is ... the University of Netherlands have carried out a...on the triptans, covering over 18,000 patients. Th...
...it shows that warfarin and aspirin are equally eff...ients at risk. Aspirin prevents blood clotting by ...arfarin acts on the levels of blood clotting prote...s in the brain that lead to strokes. Till date, it...
...smallpox vaccine is being tested against cervical ...with 95% of cervical cancer cases, but not everyon...cer affects about 465,000 women worldwide each yea...d treated in its earliest stages there is a high s...
Other Medicine News:(Date:8/28/2008)... VIENNA, Austria, Aug. 28 /- Inte...aborator Merck & Co., Inc. has initiated a Phase I...ne for the prevention of,Staphylococcus aureus (S....,placebo controlled study aims to evaluate the saf... patients with end-stage kidney disease on,hemodia...
(Date:8/27/2008)... - Patients in the VELCADE, melphalan and predn...nefit as well as a 30 percent complete response -,...nium: The Takeda,Oncology Company today announced ...andomized, Phase III VISTA(1) trial in this week,s...he results showed a significant survival,benefit a...
(Date:8/27/2008)... - First Phase 3 data, from BLISS-52 trial, e...trial, BLISS-76, expected by fall 2009 -, ROCKVIL...enome,Sciences, Inc. (Nasdaq: HGSI ) today announ... in BLISS-76, the second of two pivotal Phase 3,ra...umab) in patients with,active systemic lupus eryth...
(Date:8/26/2008)... INDIANAPOLIS, Aug. 26 /- Semafor...th International Congress on Targeted Therapies,in...ery of novel,multi-targeted kinase inhibitors that...eclinical studies., A novel and proprietary molec...al modeling allowing for the design of pan-PI3 kin...
Breaking Medicine Technology:Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Medicare Prescription Drug Benefit Nonprofit Hospitals Ambulatory Surgery Centers Statistical Methods and Pay For Performance Highlighted In the L 1162 1Medicare Prescription Drug Benefit Nonprofit Hospitals Ambulatory Surgery Centers Statistical Methods and Pay For Performance Highlighted In the L 1162 2Medicare Prescription Drug Benefit Nonprofit Hospitals Ambulatory Surgery Centers Statistical Methods and Pay For Performance Highlighted In the L 1162 3Spectranetics to Appeal Decision in Patent Litigation 1160 1Spectranetics to Appeal Decision in Patent Litigation 1160 2Spectranetics to Appeal Decision in Patent Litigation 1160 3Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 552 1Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 552 2ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference 550 1ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference 550 2... Calif.--(BUSINESS WIRE)--Jun 11, 2007 - Geron,Cor...ation of,research studies indicating that GRNOPC1,...sed therapeutic for the treatment of,spinal cord i...system., Presented by Geron scientist Ross Okamura...s meeting in San Diego, the findings,could mean th...
..., June 11, 2007-ReGen is pleased to announce that,... Colostrinin, its,nutraceutical product which the ...thy cognitive function, was presented today at the...n Surfers,Paradise, Queensland, Australia by Dr Ma...he conference, which is being attended by key opin...
Other Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia 2Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
...clusive Measuring System delivers precise and accu...eel they are receiving a better examination when t...ipment. ,User Friendly - after only 5 minutes of...ome very proficient in the operation of this instr...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve
Medicine Products: